11/15
01:19 pm
blte
Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at Maxim Group from $60.00 to $110.00. They now have a "buy" rating on the stock.
Low
Report
Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at Maxim Group from $60.00 to $110.00. They now have a "buy" rating on the stock.
11/13
12:53 pm
blte
Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at HC Wainwright from $60.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Belite Bio, Inc (NASDAQ: BLTE) had its price target raised by analysts at HC Wainwright from $60.00 to $100.00. They now have a "buy" rating on the stock.
11/12
01:00 am
blte
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Medium
Report
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
11/5
08:00 am
blte
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
Low
Report
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
11/3
04:00 pm
blte
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
Low
Report
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
10/14
08:00 am
blte
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Low
Report
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
10/8
08:00 am
blte
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
Medium
Report
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
9/24
09:57 am
blte
Here's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn Situation [Yahoo! Finance]
9/12
08:10 am
blte
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
9/10
08:00 am
blte
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
Low
Report
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
9/3
08:00 am
blte
Belite Bio to Participate in Three Upcoming Investor Conferences
Low
Report
Belite Bio to Participate in Three Upcoming Investor Conferences
9/3
07:16 am
blte
Belite Bio names Hendrik P. N. Scholl as chief medical officer [Seeking Alpha]
Low
Report
Belite Bio names Hendrik P. N. Scholl as chief medical officer [Seeking Alpha]
9/1
08:33 am
blte
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer [Financial Post (Toronto, Ontario, Canada)]
9/1
08:00 am
blte
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
Low
Report
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer